Halozyme Therapeutics, Inc. (HALO)

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

13 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• D. E. Shaw, D. E. Shaw & Co., Inc.$157.05M · 0.1% of book
• Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$133.42M · 0.1% of book
• Two Sigma, TWO SIGMA INVESTMENTS, LP$129.40M · 0.1% of book
• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$61.49M · 0.0% of book
• Joel Greenblatt, Gotham Asset Management, LLC$57.86M · 0.1% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in HALO

Trades in HALO disclosed by members of Congress and executive-branch officials, latest first:

• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 9 Mar 2026 · disclosed 7 Apr 2026
• Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 24 Mar 2025 · disclosed 7 Apr 2025
• Daniel Goldman · HouseSell · $15,001 - $50,000 · traded 12 Jul 2023 · disclosed 13 Aug 2023
• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 22 Oct 2020 · disclosed 5 Nov 2020

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions